A new lobbying partnership aimed at preventing government drug-price intervention is unfazed by President-elect Donald Trump’s anti-pharma salvo from his first press conference on Wednesday.
The President-elect’s comments didn’t surprise Joel White, the president of Horizon Government Affairs and the new head of the Rx Value Campaign, which was formed to oppose government intervention on pharmaceutical pricing in favor of free-market solutions. The coalition’s mission was first reported in Politico earlier Wednesday morning.
“The president-elect is a populist president, and he’s channeling some populist frustration,” White said. “There’s obviously nothing coordinated here, but this is an issue that’s been around for a number of years.”